Material-based neuroimaging and biomarker detection for central nervous system disorder

This is the authors' abstract. We don't add key points for this paper.

Central nervous system (CNS) disorders, including neurodegenerative diseases, brain tumors, and cerebrovascular conditions, remain difficult to detect at early stages due to nonspecific clinical manifestations, limited sensitivity of conventional diagnostic methods, and the restrictive nature of the blood-brain barrier (BBB). Recent advances in nanomaterials offer transformative potential for neuroimaging and biomarker detection, enabling high resolution, targeted, and multimodal diagnostics. This review summarizes progress in material-based magnetic resonance imaging, positron emission tomography, and emerging modalities such as photoacoustic, near-infrared, and surface-enhanced Raman scattering imaging, as well as nanoparticle-enabled biosensors for detecting Aβ, tau, α-synuclein, neurofilament light chain, and microRNAs in cerebrospinal fluid, blood, and other biofluids. The integration of multimodal imaging platforms with artificial intelligence and high-throughput optimization offers improved BBB penetration, targeting precision, and patient-specific diagnostic strategies. Future translation will depend on rigorous safety profiling, standardized performance metrics, and validation in large multicenter trials. Collectively, these material-enabled platforms are poised to advance precision diagnostics and therapeutic monitoring, offering new possibilities for improving clinical outcomes in CNS disorders.